HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
rolafagrel
RN given refers to parent cpd
Also Known As:
5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid; FCE 22178; FCE-22178; rolafagrel, sodium salt
Networked:
7
relevant articles (
2
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
rolafagrel: 7
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Naphthalenes: 18
rolafagrel: 7
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Naphthalenes: 18
rolafagrel: 7
Related Diseases
1.
Proteinuria
04/01/1995 - "
A significant reduction in proteinuria (9 +/- 1.6 vs. 17.3 +/- 2.4 mg/24 hr in FCE 22178 vs. saline, P < 0.01) and glomerular lesions was observed up to 30 weeks but not at 37 weeks.
"
09/01/1990 - "
Oral administration (150 mg.kg-1 from 1 to 14 months of age) of FCE 22178 suppressed enhanced glomerular TXB2 production at all experimental times (mean inhibition 80%) and proteinuria (varying between 27.1 and 73.0%) while preserving renal blood flow and glomerular filtration rate.
"
10/01/1994 - "
These findings suggest that the beneficial effect of FCE 22178 on the dyslipoproteinemia of nephrotic MNS rats is secondary to the amelioration in kidney function and to the reduction of proteinuria produced by this drug.
"
05/01/1989 - "
The protective effect of L-652,731 on proteinuria in the autologous phase and on glomerular filtration rate in both phases was superior to that of FCE-22178.
"
10/01/1994 - "
In the present study we investigated the effect of FCE 22178 on the plasma lipoproteins of MNS rats at 28 weeks of age (with mild proteinuria and moderate dyslipoproteinemia) and at 48 weeks of age (with heavy proteinuria and severe dyslipoproteinemia).
"
2.
Diabetic Nephropathies (Diabetic Nephropathy)
03/01/1993 - "
We measured in a double-blind, randomized, placebo-controlled crossover study the effect of a thromboxane synthase inhibitor (FCE 22178, 400 mg two or three times per day) on urinary excretion of thromboxane B2 and 6-keto-prostaglandin F1 alpha, glomerular filtration rate (measured as clearance of polyfructosan), effective renal plasma flow (clearance of para-aminohippuric acid), fractional clearances of albumin and immunoglobin G and the reabsorption rate of beta 2-microglobulin in 15 patients with type 1 (insulin-dependent) diabetic nephropathy.
"
3.
Dyslipidemias (Dyslipidemia)
10/01/1994 - "
FCE 22178 reduced the elevation in plasma HDL1 (by 17.4%) and HDL2 levels (by 30%), a key feature of nephrotic dyslipoproteinemia in the rat.
"
10/01/1994 - "
These findings suggest that the beneficial effect of FCE 22178 on the dyslipoproteinemia of nephrotic MNS rats is secondary to the amelioration in kidney function and to the reduction of proteinuria produced by this drug.
"
10/01/1994 - "
In the present study we investigated the effect of FCE 22178 on the plasma lipoproteins of MNS rats at 28 weeks of age (with mild proteinuria and moderate dyslipoproteinemia) and at 48 weeks of age (with heavy proteinuria and severe dyslipoproteinemia).
"
4.
Nephrotic Syndrome (Syndrome, Nephrotic)
10/01/1994 - "
We have previously shown that the administration of a thromboxane A2 (TXA2) synthase inhibitor (FCE 22178) reduced the progression of glomerular lesions and proteinuria in MNS rats, an inbred strain which develops an age-related nephrotic syndrome.
"
5.
Kidney Diseases (Kidney Disease)
01/01/1991 - "
Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease.
"
Related Drugs and Biologics
1.
Thromboxanes
2.
Thromboxane B2
3.
p-Aminohippuric Acid (p-Aminohippurate)
4.
Insulin (Novolin)
5.
beta 2-Microglobulin (beta 2 Microglobulin)
6.
Albumins
7.
polyfructosan (Fructan S)
8.
Lipoproteins (Lipoprotein)
9.
Thromboxane A2 (A2, Thromboxane)
10.
Copper
Related Therapies and Procedures
1.
Oral Administration